Press Releases

InspireMD Announces Presentation of Preliminary Cumulative Three-Year CGuard™ EPS Safety and Efficacy Data at the Transcatheter Cardiovascular Therapeutics 2018 Conference

Preliminary Three-Year Data Continue to Show Unprecedented Safety, Efficacy and Durability of Stroke Prevention in Treating Carotid Artery Stenosis Tel Aviv, Israel— September 27, 2018 – InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of carotid artery disease, today announced that… Read More

InspireMD Announces Issuance of Two New U.S. Patents Covering Proprietary MicroNet™ Stent Jacket and Related Drug Eluting Technology

Patents further strengthen intellectual property surrounding Company’s lead commercial product, CGuard™ EPS  InspireMD remains on track to submit an Investigational Device Exception (IDE) with FDA in mid-2019 Tel Aviv, Israel— September 17, 2018 – InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the… Read More

InspireMD to Present at the H.C. Wainwright 20th Annual Global Investment Conference in New York City

Tel Aviv, Israel— September 4, 2018 – InspireMD, Inc. (NYSE American:NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of carotid artery disease, today announced it will be presenting at the H.C. Wainwright 20th Annual Global Investment Conference (previously known as the Rodman and Renshaw conference). … Read More

InspireMD Reports 94% Increase in CGuard™ EPS RevenuesInspireMD Reports 94% Increase in CGuard™ EPS Revenuesfor the Second Quarter of 2018

Tel Aviv, Israel— August 6, 2018 – InspireMD, Inc. (NYSE American:NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of carotid artery disease, today announced results for the second quarter ending June 30, 2018. Second Quarter 2018 highlights: Revenues in Q2 of $1.0 million for 2018… Read More

InspireMD Schedules Second Quarter 2018 Earnings Conference Call

Tel Aviv – July 31, 2018 – InspireMD, Inc. (NYSE: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of carotid artery disease, today announced that it will host a conference call on Tuesday, August 7th at 8:00 a.m. Eastern Time to discuss the company’s financial… Read More

InspireMD Announces Opening of First Two CGuard™ EPS Centers of Excellence

Tel Aviv, Israel— July 23, 2018 – InspireMD, Inc. (NYSE AMER: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of carotid artery disease, today announced that it has established its first two Centers of Excellence (COE) at leading hospitals in Europe. The first COE is… Read More

InspireMD, Inc. Announces Pricing of $10 Million Underwritten Public Offering

Tel Aviv, Israel— June 29, 2018 – InspireMD, Inc. (NYSE American: NSPR), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today announced the pricing of an underwritten public offering of 33,333,333 units at a price to the public of $0.30 per unit. InspireMD expects to receive aggregate gross proceeds… Read More